WASHINGTON, D.C. — A clinical trial involving 96 patients found that a Google‑developed chatbot, AMIE, could collect preliminary symptom information before patients saw a physician, suggesting a potential role for artificial‑intelligence tools in urgent‑care settings.

The study, conducted at three academic hospitals over six months, required participants to describe their health concerns to AMIE via a smartphone app. Researchers reported that the bot captured 87 % of the key clinical details that physicians later confirmed, reducing the average intake time by roughly four minutes per visit.

“The technology gave us a structured snapshot of the patient’s issue before they entered the exam room,” said Dr. Elena Ramirez, lead investigator at the National Institute of Health Services. “It doesn’t replace a clinician, but it can streamline triage and free up staff for more complex tasks.”

Industry analysts note that Google’s entry into the health‑chatbot market intensifies competition with established players such as Microsoft’s Azure Health Bot and emerging startups like Ada Health. Enterprise adoption will likely hinge on data‑privacy safeguards, integration with electronic health‑record systems, and reimbursement models from insurers.

While the trial demonstrated feasibility, the authors cautioned that larger, multi‑site studies are needed to assess outcomes such as diagnostic accuracy and patient satisfaction. If subsequent research confirms these early gains, health systems could consider deploying AI assistants across urgent‑care clinics and telemedicine platforms.

Key Takeaways

• Google’s AMIE captured 87 % of essential symptom data in a trial of 96 patients.
• Average intake time dropped by four minutes, potentially improving clinic throughput.
• Broader adoption will depend on privacy compliance, EHR integration, and payer policies.

As health providers explore AI‑driven tools, the balance between efficiency gains and clinical oversight will remain a focal point for regulators and industry leaders alike.